Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
NEW YORK, Sept. 01, 2017 -- Stull, Stull & Brody ("SS&B") reminds investors that a class action lawsuit was commenced in the United States District Court for the Southern District of Ohio on behalf of purchasers of Teva Pharmaceutical Industries Limited’s (“Teva”) American Depository Shares (“ADS”) (NYSE:TEVA), between February 9, 2015 and November 3, 2016 (“Class Period”), in Teva’s voluntary and contributory employee benefit plans. If you contributed money in any of Teva’s voluntary employee benefit plans and acquired Teva ADSs as a result of such contributions, your rights may be affected.
The complaint alleges, among other claims, that Teva’s Registration Statement filed with the Securities and Exchange Commission violated Section 11 of the Securities Act of 1933 by omitting material facts and otherwise containing inaccurate, misleading and untrue statements of fact pertaining to Teva’s business and its operational and financial results, and more specifically relating to Teva’s Foreign Corrupt Practices Act (“FCPA”) compliance and the alleged price fixing of generic drugs.
If you have any questions concerning this notice or your rights or interests with respect to these matters, you may contact Michael Klein, Esq. of SS&B at [email protected], telephone 1-212-687-7230 x147, or by fax to 212-490-2022.
SS&B has litigated class actions for violations of securities laws and breaches of fiduciary duty on behalf of defrauded investors over the past 40 years and has obtained court approval of substantial settlements on numerous occasions. SS&B has offices in New York and Beverly Hills. SS&B’s website (www.ssbny.com) has additional information about the firm.
Attorney advertising. Prior results do not guarantee a similar outcome. This press release may be considered Attorney Advertising in some jurisdictions under applicable laws and ethical rules.
